If a company builds assets at 20.9% a year, faster than its revenue growth rate of 11.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Zhejiang Wolwo Bio-Pharmaceutical Co's average Total Assets Growth Rate was 21.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 20.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 20.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 19.80% per year.
During the past 13 years, Zhejiang Wolwo Bio-Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 42.20%. The lowest was 3.00%. And the median was 22.20%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Zhejiang Wolwo Bio-Pharmaceutical Co Total Assets Chart
Zhejiang Wolwo Bio-Pharmaceutical Co Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Wolwo Bio-Pharmaceutical Co (SZSE:300357) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Zhejiang Wolwo Bio-Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Zhejiang Wolwo Bio-Pharmaceutical Co Total Assets Related Terms
Thank you for viewing the detailed overview of Zhejiang Wolwo Bio-Pharmaceutical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhejiang Wolwo Bio-Pharmaceutical Co (SZSE:300357) Business Description
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300357 has been successfully added to your 